-transparent.png){kind=logo}
Effective dose range of candesartan cilexetil for systemic hypertension. Candesartan Cilexetil Study Investigators. 1999
T P Bell, and
V DeQuattro, and
K C Lasseter, and
D Ruff, and
J D Hardison, and
D Cushing, and
A E Kezer, and
E L Michelson
University of South Alabama Medical Center, Mobile, USA.
The results of this randomized, double-blind, placebo-controlled, forced-dose titration study in a diverse population of hypertensive patients in the US indicate that candesartan cilexetil has clinically meaningful dose-related blood pressure-lowering effects and that maximum blood pressure reduction is achieved with doses of 16 and 32 mg given once daily. This study confirms that candesartan cilexetil is a highly effective antihypertensive agent with an excellent tolerability and safety profile, without dose-related adverse effects.
Related Publications
T P Bell, and
V DeQuattro, and
K C Lasseter, and
D Ruff, and
J D Hardison, and
D Cushing, and
A E Kezer, and
E L Michelson
October 1998,
The American journal of cardiology,
T P Bell, and
V DeQuattro, and
K C Lasseter, and
D Ruff, and
J D Hardison, and
D Cushing, and
A E Kezer, and
E L Michelson
August 1999,
The American journal of cardiology,
T P Bell, and
V DeQuattro, and
K C Lasseter, and
D Ruff, and
J D Hardison, and
D Cushing, and
A E Kezer, and
E L Michelson
March 1999,
Clinical therapeutics,
T P Bell, and
V DeQuattro, and
K C Lasseter, and
D Ruff, and
J D Hardison, and
D Cushing, and
A E Kezer, and
E L Michelson
November 1999,
The American journal of cardiology,
T P Bell, and
V DeQuattro, and
K C Lasseter, and
D Ruff, and
J D Hardison, and
D Cushing, and
A E Kezer, and
E L Michelson
March 2001,
The American journal of cardiology,
T P Bell, and
V DeQuattro, and
K C Lasseter, and
D Ruff, and
J D Hardison, and
D Cushing, and
A E Kezer, and
E L Michelson
September 1997,
Journal of human hypertension,
T P Bell, and
V DeQuattro, and
K C Lasseter, and
D Ruff, and
J D Hardison, and
D Cushing, and
A E Kezer, and
E L Michelson
January 2012,
Profiles of drug substances, excipients, and related methodology,
T P Bell, and
V DeQuattro, and
K C Lasseter, and
D Ruff, and
J D Hardison, and
D Cushing, and
A E Kezer, and
E L Michelson
January 1999,
Heart disease (Hagerstown, Md.),
T P Bell, and
V DeQuattro, and
K C Lasseter, and
D Ruff, and
J D Hardison, and
D Cushing, and
A E Kezer, and
E L Michelson
January 2000,
Heart disease (Hagerstown, Md.),
T P Bell, and
V DeQuattro, and
K C Lasseter, and
D Ruff, and
J D Hardison, and
D Cushing, and
A E Kezer, and
E L Michelson
September 2000,
Hypertension (Dallas, Tex. : 1979),
